Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Pityriasis Rubra Pilaris Clinical Trial

Official title: An Open Label Pilot Trial of Guselkumab in the Treatment of Adults With Pityriasis Rubra Pilaris (PRP)

Status Completed

Clinical Trial Summary

15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit. 3 visits in between these times and one follow up visit may be performed by secure videoconferencing.

Clinical Trial Description

Pityriasis rubra pilaris (PRP) is a rare and poorly understood severe inflammatory skin disease characterized by widespread (often full-body) redness and flaking of the skin, painful thickening and cracking of the palms and soles, hair loss, crumbling nails, and severe skin itching and burning.

There is no FDA-approved therapy for this rare disease and the commonly used medications do not work for many patients. There is some evidence that interleukin (IL)-23 may be too high in the skin of PRP patients. Ixekizumab is an injectable medication that blocks IL-23 by binding the p19 subunit and is FDA-approved for psoriasis. ;

Related Conditions & MeSH terms

• Dermatitis, Exfoliative
• Pityriasis Rubra Pilaris

• NCT number: NCT03975153
• Study type: Interventional
• Source: Oregon Health and Science University
• Status: Completed
• Phase: Phase 2
• Start date: October 3, 2019
• Completion date: March 22, 2024